<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00702247</url>
  </required_header>
  <id_info>
    <org_study_id>00019702/3174</org_study_id>
    <nct_id>NCT00702247</nct_id>
  </id_info>
  <brief_title>Tandem Autologous- Nonmyeloablative Allogeneic Transplant for Newly Diagnosed Multiple Myeloma (Trapianto Tandem Autologo-Allogenico Non Mieloablativo Nel Mieloma Alla Diagnosi)</brief_title>
  <official_title>Allogeneic Stem Cell Transplantation for Multiple Myeloma: a Two Step Approach to Reduce Toxicity Involving High-Dose Melphalan and Autologous Stem Cell Transplant Followed by PBSC Allografting After Low-Dose TBI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera San Giovanni Battista</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliera San Giovanni Battista</source>
  <brief_summary>
    <textblock>
      To evaluate toxicity profile and efficacy of a tandem autologous-nonmyeloablative transplant
      approach in newly diagnose myeloma patients younger than 65 years
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 1999</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>yearly</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>event free survival</measure>
    <time_frame>yearly</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hematopoietic Stem Cell Transplantation</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Durie-Salmon stage IIA-IIIB multiple myeloma

          -  Age &gt; 18 and ≤ 65 years

          -  Previously untreated myeloma

          -  Presence of a sibling (potential donor)

          -  Bilirubins &lt; twice normal;ALAT and ASAT &lt; four times normal

          -  Left ventricular ejection fraction &gt; 40%

          -  Creatinine clearances &gt; 40 mL/min

          -  Pulmonary dysfunction with diffusing capacity for carbon monoxide (DLCO) &gt; 40% and/or
             need for continuous oxygen supplementation

          -  Karnofsky performance status &gt; 60%

          -  Patients must give written informed consent

        Exclusion Criteria:

          -  Age &gt; 65 years

          -  Previously treated myeloma

          -  Absence of a sibling (genetic randomisation cannot be applied)

          -  Karnofsky performance status score &lt; 60%

          -  HIV-infection

          -  Pregnancy

          -  Refusal to use contraceptive techniques during and for 12 months following treatment

          -  Patients unable to give written informed consent

          -  PS. Informed consent is obtained from each patient according to the Institutional
             Review Boards of the participating centers. The study is conducted according to the
             Declaration of Helsinki.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno Benedetto, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Torino - Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Benedetto Bruno, MD, PhD</last_name>
    <phone>+39-011-6334419</phone>
    <email>benedetto.bruno@unito.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Università di Torino - Azienda Ospedaliera S.Giovanni Battista</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benedetto Bruno, MD, PhD</last_name>
      <phone>+39-011-6334419</phone>
      <email>benedetto.bruno@unito.it</email>
    </contact>
    <contact_backup>
      <last_name>Mario Boccadoro</last_name>
      <phone>+39-011-6336728</phone>
      <email>mario.boccadoro@unito.it</email>
    </contact_backup>
    <investigator>
      <last_name>Benedetto Bruno, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2008</study_first_submitted>
  <study_first_submitted_qc>June 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2008</study_first_posted>
  <last_update_submitted>June 19, 2008</last_update_submitted>
  <last_update_submitted_qc>June 19, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2008</last_update_posted>
  <keyword>Multiple Myeloma - Nonmyeloablative transplantation - Autologous Transplant - Graft versus myeloma</keyword>
  <keyword>Newly diagnosed multiple myeloma</keyword>
  <keyword>Tandem Auto-Allo Transplant</keyword>
  <keyword>Overall survival</keyword>
  <keyword>Event free survival</keyword>
  <keyword>Disease response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

